v3.22.2.2
Acquisition (Details Narrative) - USD ($)
12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Shares of Common stock 833,334  
Acquisition payable $ 0 $ 1,764,876
Proceeds from issuance of common stock 0 10,950,315
Net (loss) income (2,046,030) 2,978,948
Amortized of intangible assets 2,159,146 726,525
Revenues $ 44,584,996 24,095,025
FinderFee [Member]    
Common stock per share $ 4.82  
Cash payment $ 70,000  
Common stock issued during period for acquisition value $ 33,740  
Common stock issued during period for acquisition 7,000  
Finder's fee $ 103,740  
Purchase method of accounting [Member]    
Total estimated fair value $ 3,556,589  
Shares of Common stock 100,000  
Common stock per share $ 4.82  
Acquisition payable $ 74,589  
Cash payment $ 2,000,000  
Purchase price sale of shares 100,000  
Proceeds from issuance of common stock $ 482,000  
Convertible per share $ 5.00  
Proceeds from repayment of loans to purchase common stock $ 500,000  
Original principal amount 500,000  
VitaMedica [Member]    
Amortization expense annually 496,356  
Amortization expense monthly 41,363  
Net (loss) income 35,596 380,047
Amortized of intangible assets 454,988  
Revenues 5,124,583  
Net income (loss) 224,735  
amortization expense of definite lived intangible assets 1,767,350 3,200,304
VitaMedica [Member] | Proforma Adjustments [Member]    
Amortization expense $ 41,363 496,356
July 1, 2020 [Member]    
Shares of Common stock 222,223  
Common stock per share $ 1.53  
Additional shares of common stock consideration 1,535,781  
Shares of Common stock 304,181  
July 1, 2020 [Member] | Infusionz LLC [Member]    
Outstanding interest 100.00%  
Cash $ 350,000  
Consideration 3,000,000  
Total estimated fair value $ 3,350,000  
Shares of Common stock 833,334  
Common stock per share $ 3.60  
Description of public offering if the ‘offering price’ of the Company’s successful underwritten initial public offering of the Company’s Common Stock is lower than $3.60 per share (post reverse split), the Company shall promptly issue such additional shares proportionately to each of the Sellers necessary to bring the value of the equity consideration to a total of $3,000,000  
Reverse split description the Company issued 222,223 shares of Common Stock (post-reverse split) to the Sellers, based on the most recent price of $1.53 per share of Common Stock  
Accrued acquisition payable   2,424,745
September 1,2021 [Member]    
Shares of Common stock 306,935  
September 1,2021 [Member] | Infusionz LLC [Member]    
Shares of Common stock 306,945  
Common stock per share $ 1.53  
November 1, 2020 [Member]    
Shares of Common stock 101,392  
November 1, 2020 [Member] | Infusionz LLC [Member]    
Shares of Common stock 101,389  
Common stock per share $ 1.53  
January 4, 2021 [Member] | Infusionz LLC [Member]    
Consideration $ 75,000  
February 1, 2021 [Member] | Infusionz LLC [Member]    
Shares of Common stock 101,392  
Common stock per share $ 1.53  
June 25, 2021 [Member] | Infusionz LLC [Member]    
Shares of Common stock 101,400  
Common stock per share $ 5.75  
Interactive Offers LLC    
Shares of Common stock 560,170  
Common stock per share $ 4.88  
Cash payment $ 2,100,000  
Amortization expense annually 603,948  
Amortization expense monthly 50,329  
Amortized of intangible assets 452,963  
Common stock issued during period for acquisition value 4,833,630  
Proceeds from issuance of common stock 2,733,630  
Net income (loss) 1,160,160  
Asset purchase price $ 4,833,630  
Cygnet Online, LLC    
Shares of Common stock 555,489  
Common stock per share $ 6.00  
Cash payment $ 1,500,000  
Purchase price sale of shares 5,100,000  
Proceeds from issuance of common stock $ 2,550,000  
Original principal amount $ 1,050,000  
Description In addition, the Company has the right to purchase Seller’s remaining membership interests in Cygnet. Commencing on October 10, 2022 and continuing for 180 days thereafter, the Company has the right, but not the obligation, to cause the Seller to sell 15% of the membership interests in Cygnet for $1,650,000 in immediately available funds. Commencing on the date that the Company completes its financial statements for the year ended December 31, 2023, and continuing for 120 days thereafter, the Company has the right, but not the obligation, to cause the Seller to sell the remaining 30% of the membership interests in Cygnet for 30% of the amount equal to four times Cygnet’s Adjusted EBITDA (as defined in the Call Agreement) for calendar year 2023, payable by wire transfer of immediately available funds equal to at least 50% of said purchase price with the balance payable through the issuance to Seller of shares of restricted common stock of the Company  
Description of earn-out payment Additionally, Seller will be paid up to $700,000 in the form of an earn-out payment based on 7% of Cygnet’s net revenue during the earn-out period, in accordance with and subject to the terms and conditions of the agreement. The earn-out payment, if any, will be paid 50% in immediately available funds and 50% in Company restricted common stock  
Amortization expense annually $ 2,100,000  
Amortization expense monthly 175,000  
Net (loss) income 152,981  
Amortized of intangible assets 525,000  
Revenues 7,634,153  
Proforma Adjustments [Member]    
Net (loss) income (1,767,350) (3,200,304)
Proforma Adjustments [Member] | Interactive Offers LLC    
Amortization expense 150,987 603,948
Proforma Adjustments [Member] | Cygnet Online, LLC    
Amortization expense $ 1,575,000 $ 2,100,000